Research Article
The Prevalence of MRSA Nasal Carriage in Preoperative Pediatric Orthopaedic Patients
Table 1
Characteristics of the 699 patients included in the study with special emphasis on patients who tested MRSA positive on admission.
| | | MRSA+ | MRSA− | Total | | | SSI+, (%) | SSI−, (%) | SSI+, (%) | SSI−, (%) | (%) | | | () | () | () | () | () |
| | Age, mean (range) | 5.55 (0–18) | 8.14 (0–17) | 6.67 (0–15) | 8.91 (0–18) | 9.54 (0–18) | | Gender | | | | | | | Male | 7 (77.8) | 21 (60.0) | 6 (60.0) | 352 (54.6) | 386 (55.2) | | Female | 2 (22.2) | 14 (40.0) | 4 (40.0) | 293 (45.4) | 313 (44.8) | | Location prior to hospitalization | | | | | | | Home | 7 (77.28) | 29 (82.9) | 9 (90.0) | 593 (91.9) | 638 (91.3) | | Newborn | 2 (22.2) | 3 (8.57) | 0 (0.0) | 18 (2.8) | 23 (3.3) | | Group home | 0 (0.0) | 1 (2.85) | 0 (0.0) | 3 (0.5) | 4 (0.6) | | Other hospital | 0 (0.0) | 2 (5.71) | 1 (10.0) | 31 (4.8) | 34 (4.9) | | Prior hospitalization in last 5 years | | | | | | | Yes | 8 (88.9) | 26 (74.3) | 5 (50.0) | 331 (51.3) | 370 (52.9) | | No | 1 (11.1) | 9 (25.7) | 5 (50.0) | 314 (48.7) | 329 (47.1) | | Diagnosis | | | | | | | Myelomeningocele | 8 (88.9) | 10 (28.6) | 4 (40.0) | 181 (28.1) | 203 (29.0) | | Cerebral palsy | 0 (0.0) | 3 (8.6) | 0 (0.0) | 34 (5.3) | 37 (5.3) | | Trauma | 0 (0.0) | 6 (17.1) | 1 (10.0) | 149 (23.1) | 156 (22.3) | | Tumor | 0 (0.0) | 2 (5.7) | 1 (10.0) | 52 (8.1) | 55 (7.9) | | Infection | 1 (11.1) | 7 (20.0) | 1 (10.0) | 34 (5.3) | 43 (6.2) | | Scoliosis | 0 (0.0) | 2 (5.71) | 0 (0.0) | 95 (14.7) | 97 (13.9) | | Chiari malformation | 2 (22.2) | 1 (2.85) | 2 (20.0) | 33 (5.1) | 38 (5.4) | | Other | 1 (11.1) | 9 (25.7) | 3 (30.0) | 142 (22.0) | 154 (22.0) | | Surgery | | | | | | | Neurosurgery | 9 (100) | 20 (57.1) | 9 (90.0) | 359 (55.7) | 397 (56.8) | | Orthopaedic surgery | 0 (0.0) | 15 (42.9) | 1 (10.0) | 286 (44.3) | 302 (43.2) | | Wound class | | | | | | | Clean | 9 (100.0) | 24 (68.6) | 10 (100.0) | 590 (91.5) | 633 (90.6) | | Clean-contaminated | 0 (0.0) | 8 (22.9) | 0 (0.0) | 38 (5.9) | 46 (6.6) | | Contaminated | 0 (0.0) | 3 (8.6) | 0 (0.0) | 11 (1.7) | 14 (2.0) | | Infected | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (0.9) | 6 (0.9) | | Underlying disorder | | | | | | | Diabetes mellitus | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (0.9) | 6 (0.9) | | Immunocompromised | 1 (11.1) | 2 (5.7) | 1 (10.0) | 24 (3.7) | 28 (4.0) | | Renal disease | 4 (44.4) | 0 (0.0) | 1 (10.0) | 39 (6.0) | 44 (6.8) | | Tobacco use/exposure | | | | | | | Yes | 0 (0.0) | 1 (2.9) | 0 (0.0) | 34 (5.3) | 35 (5.0) | | No | 9 (100.0) | 34 (97.1) | 10 (100.0) | 611 (94.7) | 664 (95.0) | | Corticosteroid use (%) | | | | | | | Yes | 3 (33.3) | 6 (17.1) | 0 (0.0) | 52 (8.1) | 61 (8.7) | | No | 6 (76.7) | 29 (82.9) | 10 (100.0) | 593 (91.9) | 638 (91.3) |
|
|
Many individuals had multiple diagnoses and were thus counted twice.
|
